Tuberculosis prevention and control in long-term-care facilities for older adults

Infection Control and Hospital Epidemiology

Volumn 25, Issue 12, 2004, Pages 1097-1108

  Thrupp, Lauri ^a   Bradley, Suzanne ^b   Smith, Philip ^c   Simor, Andrew ^d   Gantz, Nelson ^e   Crossley, Kent ^f,j   Loeb, Mark ^g   Strausbaugh, Larry ^h   Nicolle, Lindsay ⁱ   Blue, Sky ^j   Gainer, R Brooks ^j   Quiros, Rodolfo ^j   Steele, Lynn ^j   Stevenson, Kurt ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e Boulder Community Hospital   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ HEALTH SCIENCES CENTRE   (Canada)

^j Bldg 53 ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AGED; AGING; AIRBORNE INFECTION; ARTICLE; ATTACK RATE; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY CARE; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DIRECTLY OBSERVED THERAPY; DRUG RESPONSE; EVIDENCE BASED MEDICINE; EXTRAPULMONARY TUBERCULOSIS; GERIATRIC CARE; HOST RESISTANCE; HUMAN; INFECTION RATE; LABORATORY DIAGNOSIS; LONG TERM CARE; LONG TERM CARE FACILITY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; NURSING HOME; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES;

AGED; AGING; ANTITUBERCULAR AGENTS; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HUMANS; INCIDENCE; LONG-TERM CARE; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; UNITED STATES;

EID: 10844243865     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502350     Document Type: Article

References (104)

1. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49:1-51.
2. American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR 2003;52:1-77.
3. Rajagopalan S. Tuberculosis and aging: a global health problem. Clin Infect Dis 2001;33:1034-1039.
4. Myers JA, Anderson HR. The significance of tuberculosis among the aged. American Review of Tuberculosis 1930;21:541-556.
5. Myers JA. Tapering off of tuberculosis among the elderly. Am J Public Health 1976;66:1101-1106.
6. Frost WH. The age selection of mortality from tuberculosis in successive decades. Am J Hygiene 1939;30A:91-96.
7. Powell KE, Farer LS. The rising age of the tuberculosis patient a sign of success and failure. J Infect Dis 1980;142:946-948.
8. Stead WW, Lofgren JP. Does the risk of tuberculosis increase with age? J Infect Dis 1983;147:951-955.
9. Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of Tuberculosis Elimination. Surveillance Reports, 2001. Atlanta, GA: Centers for Disease Control and Prevention; 2001. Available at www.cdc.gov/mmwr/preview/ mmwrhtml/mm5053a1.htm.
10. Bentley DW. Tuberculosis in long-term care facilities. Infect Control Hosp Epidemiol 1990;11:4246.
11. Centers for Disease Control and Prevention. Trends in aging: United States and worldwide. MMWR 2003;52:101-106.
12. Stead WW, To T. The significance of the tuberculin skin test in elderly persons. Ann Intern Med 1987;107:837-842.
13. Stead WW. Tuberculosis among elderly persons: an outbreak in a nursing home. Ann Intern Med 1981;94:606-610.
14. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an epidemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1985;312:1483-1487.
15. Ijaz K, Dillaha JA, Yang Z, Cave MD, Bates JH. Unrecognized tuberculosis in a nursing home causing death with spread of tuberculosis to the community. J Am Geriatr Soc 2002;50:1213-1218.
16. Morris CDW, Nell H. Epidemic of pulmonary tuberculosis in geriatric homes. S Afr Med J 1988;74:117-120.
17. American Thoracic Society, Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-1395.
18. McDonald RJ, Mulvihill MN, Hsu M-A, Libow LS, Neufeld RR. Tuberculosis surveillance in a long-term care facility. Arch Gerontol Geriatr 1992;15:29-34.
19. Heaf FRG. Tuberculosis in geriatrics. Journal of the Royal Institute of Public Health and Hygiene 1955;18:324-341.
20. Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis 1993;17:968-975.
21. Stead WW. The pathogenesis of pulmonary tuberculosis among older persons. Am Rev Respir Dis 1965;91:811-822.
22. Khan MA, Kovnat DM, Bachus B, Whitcomb ME, Brody JS, Snider GL. Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. Am J Med 1977;62:31-38.
23. Alvarez S, Shell C, Berk SL. Pulmonary tuberculosis in elderly men. Am J Med 1987;82:602-606.
24. Banyai AL. Pulmonary tuberculosis in the aged. American Review of Tuberculosis 1930;21:568-578.
25. Stead WW, Kerby GR, Schlueter DP, Jordahl CW. The clinical spectrum of primary tuberculosis in adults: confusion with reinfection in the pathogenesis of chronic tuberculosis. Ann Intern Med 1968;68:731-745.
26. Alexander WJ, Avent CK, Bailey WC. Simple primary tuberculosis in an elderly woman. J Am Geriatr Soc 1979;27:123-125.
27. Troisier J, Develay S, Weiss-Roudinesco J. Sensibilité à la tuberculine provoque chez le viellard par le BCG. Presse Medicale 1929;37:137-138.
28. Griep WA, Bleiker MA. Notes on the tuberculin test. Tubercle 1957;38:259-267.
29. Giannini D, Sloan RS. A tuberculin survey of 1285 adults with special reference to the elderly. Lancet 1957;1:525-527.
30. Beresford OD. Tuberculin skin sensitivity in old age. American Review of Tuberculosis 1958;77:323-328.
31. Caplin M, Silver CP, Wheeler WE. Tuberculin sensitivity in the middle-aged and elderly. Tubercle 1958;39:84-89.
32. Chesrow EJ, Novak JB. Tuberculin testing of the aged. Dis Chest 1967;51:635-636.
33. Robins AB, Abeles H, Aronsohn MH, et al. Tuberculin-testing studies in New York City. American Review of Tuberculosis 1954;69:1057-1058.
34. Johnston RN, Ritchie RT, Murray IBF. Declining tuberculin sensitivity with advancing age. Br Med J 1963;2:720-724.
35. Miller SD, Jones HE. Correlation of lymphocyte transformation with tuberculin skin-test sensitivity. Am Rev Respir Dis 1973;107:530-537.
36. Havlir DV, van der Kuyp F, Duffy E, Marshall R, Hom D, Ellner JJ. A 19-year follow up of tuberculin reactors: assessment of skin test reactivity and in vitro lymphocyte responses. Chest 1991;99:1172-1176.
37. Fukushima T, Nakayama K, Monma M, Sekizawa K, Sasaki H. Depression of T helper-1 and tuberculin responses in older bed-bound patients. J Am Geriatr Soc 1999;47:259-260.
38. Nagami PH, Yoshikawa TT. Tuberculosis in the geriatric patient. J Am Geriatr Soc 1983;31:356-362.
39. Stern JK, Smith PW. Tuberculosis in the long-term care facility. Geriatric Focus on Infectious Diseases 1991;1:6-10.
40. Katz PR, Reichman W, Dube D, Feather J. Clinical features of pulmonary tuberculosis in young and old veterans. J Am Geriatr Soc 1987;35:512-515.
41. Yoshikawa TT. Tuberculosis in aging adults. J Am Geriatr Soc 1992;40:178-187.
42. Yoshikawa TT. The challenge and unique aspects of tuberculosis in older patients. Infectious Diseases in Clinical Practice 1994;3:62-66.
43. Rudd A. Tuberculosis in a geriatric unit. J Am Geriatr Soc 1985;33:566-569.
44. Morris CDW. Pulmonary tuberculosis in the elderly: a different disease? Thorax 1990;45:912-913.
45. Leung CC, Yew WW, Chan CK, et al. Tuberculosis in older people: a retrospective and comparative study from Hong Kong. J Am Geriatr Soc 2002;50:1219-1226.
46. Perez-Guzman C, Vargas MH, Torres-Cruz A, Villarreal-Velarde H. Does aging modify pulmonary tuberculosis? A meta-analytical review. Chest 1999;116:961-967.
47. Sahn SA, Neff TA. Miliary tuberculosis. Am J Med 1974;56:495-505.
48. Price LE, Rutala WA. Tuberculosis screening in the long-term care setting. Infect Control 1987;8:353-356.
49. Robertson JM, Burtt DS, Edmonds KL, et al. Delayed tuberculin reactivity in persons of Indochinese origin: implications for preventative therapy. Ann Intern Med 1996;124:779-784.
50. Muder RR, Brennen CI, Yu KT. Choosing appropriate criteria for tuberculin positivity and conversion in a long-term care facility. Infect Control Hosp Epidemiol 1993;14:523-526.
51. Blumberg HM, White N, Parrott P, Gordon W, Hunter M, Ray S. False-positive tuberculin skin test results among health care workers. JAMA 2000;283:2793.
52. Clemens JD, Choung JJH, Feinstein AR. The BCG controversy: a methodological and statistical appraisal. JAMA 1983;249:2362-2369.
53. Hoft DF, Tennant JM. Persistence and boosting of bacille Calmette-Guèrin-induced delayed-type hypersensitivity. Ann Intern Med 1999;131:32-36.
54. Centers for Disease Control. Prevention and control of tuberculosis in facilities providing long-term care to the elderly. MMWR 1990;39:7-20.
55. Slovis BS, Plitman JD, Haas DW. The case against anergy testing as a routine adjunct to tuberculin skin testing. JAMA 2000;283:2003-2007.
56. Thompson NJ, Glassroth JL, Snider DE, et al. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979;119:587-597.
57. Barry MA, Regan AM, Kunches LM, Harris ME, Bunce SA, Craven DE. Two-stage tuberculin testing with control antigens in patients residing in two chronic disease hospitals. J Am Geriatr Soc 1987;35:147-152.
58. Simon JA, McVicker SM, Ferrell CR, Payne CM. Two-step tuberculin testing in a veterans domiciliary population. South Med J 1983;76:866-869.
59. Centers for Disease Control and Prevention. Guideline for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR 2003;52:15-18.
60. Nelson SM, Deike MA, Cartwright CP. Value of examining multiple sputum specimens in the diagnosis of pulmonary tuberculosis. J Clin Microbiol 1998;36:467-469.
61. Kox LFF. Tests for detection and identification of mycobacteria: how should they be used? Respiratory Medicine 1995;89:399-408.
62. Shinnick TM, Good RC. Diagnostic mycobacteriology practices. Clin Infect Dis 1995;21:291-299.
63. Cucin RL, Coleman M, Eckardt JJ, Silver RT. The diagnosis of miliary tuberculosis: utility of peripheral blood abnormalities, bone marrow, and liver needle biopsy. J Chronic Dis 1973;26:355-361.
64. Strumpf IJ, Tsang AY, Sayre WJ. Re-evaluation of sputum straining for the diagnosis of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:599-602.
65. Gordin F, Slutkin G. The validity of acid-fast smears in the diagnosis of pulmonary tuberculosis. Arch Pathol Lab Med 1990;114:1025-1027.
66. Tenover FC, Crawford JT, Huebner RE, Gefter LJ, Horsburgh CR Jr, Good RC. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol 1993;31:767-770.
67. Hanna BA, Ebrahimzadeh A, Elliott LB, et al. Multicenter evaluation of the BACTEC MGIY 960 system for recovery of mycobacteria. J Clin Microbiol 1999;37:748-762.
68. Brunello F, Favari F, Fontana R. Comparison of the MB/BacT and BACTEC 460 TB systems for recovery of mycobacteria from various clinical specimens. J Clin Microbiol 1999;37:1206-1209.
69. Gonzalez R, Hanna BA. Evaluation of Gen-Probe DNA hybridization systems for the identification of Mycobacterium tuberculosis and Mycobacterium avium-intracellular. Diagn Microbiol Infect Dis 1987;8:69-77.
70. Musial CE, Tice LS, Stockman L, Roberts GD. Identification of mycobacteria from culture by using the Gen-Probe rapid diagnostic system for Mycobacterium avium complex and Mycobacterium tuberculosis complex. J Clin Microbiol 1988;26:2120-2133.
71. Alcaide F, Benitez MA, Escribe JM, Martin R. Evaluation of the BACTEC MGIT 960 and the MB/BacT systems for recovery of mycobacteria from clinical specimens and for species identification by DNA AccuProbe. J Clin Microbiol 2000;38:398-401.
72. D'Amato RF, Wallman AA, Hochstein LH, et al. Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLIGOR Mycobacterium tuberculosis PCR test. J Clin Microbiol 1995;33:1832-1834.
73. Carpentier E, Drouillard S, Dailloux M, et al. Diagnosis of tuberculosis by Amplicor Mycobacterium tuberculosis test: a multicenter study. J Clin Microbiol 1995;33:3106-3110.
74. Vuorinen P, Miettinen A, Vuento R, Hiklistrdm O. Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by Gen-Probe Amplified Mycobacterium tuberculosis test and Roche Amplicor Mycobacterium tuberculosis test. J Clin Microbiol 1995;33:1859-1866.
75. Bennedsen J, Thomsen VO, Pfyffer GE, et al. Utility of PCR in diagnosing pulmonary tuberculosis. J Clin Microbiol 1991;34:1407-1411.
76. Piersimoni C, Callegaro A, Nista D, et al. Comparative evaluation of two commercial amplification assays for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 1997;36:193-196.
77. American Thoracic Society. Rapid diagnostic tests for tuberculosis: what is the appropriate use? Am J Respir Crit Care Med 1997;155:1804-1814.
78. Kennedy DJ, Lewis WP, Barnes PF. Yield of bronchoscopy for the diagnosis of tuberculosis in patients with HIV infections. Chest 1992;102:1040-1044.
79. Centers for Disease Control and Prevention. Nucleic acid amplification tests for tuberculosis. MMWR 1996;45:950-952.
80. Barnes PF, Cave MD. Molecular epidemiology of tuberculosis. N Engl J Med 2003;349:1149-1156.
81. Barnes PF, Yang Z, Preston-Martin S, et al. Patterns of tuberculosis transmission in central Los Angeles. JAMA 1997;278:1159-1163.
82. Centers for Disease Control and Prevention. Guidelines for preventing the transmission Mycobacterium tuberculosis in health-care facilities, 1994. MMWR 1994;43:1-132.
83. Centers for Disease Control and Prevention. Guidelines for environmental control in health-care facilities: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HIC-PAC). MMWR 2003;52:1-44.
84. Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1995;44:19-34.
85. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review). The Cochrane Library Issue 1, 2001.
86. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO 1982;60:555-564.
87. Horsburgh CR, Feldman S, Ridzon R. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis 2000;31:633-639.
88. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001.
89. Sorresso DJ, Mehta JB, Harvill LM, Bentley S. Under utilization of isoniazid chemoprophylaxis in tuberculosis contacts age 50 years of age and older: a prospective analysis. Chest 1995;108:706-711.
90. Van den Brande P, Van Steenbergen W, Vervoort G, Demedts M. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995;152:1705-1708.
91. Rose DN, Schechter CB, Silver A. The age threshold for isoniazid chemoprophylaxis. JAMA 1986;256:2709-2713.
92. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventative therapy: a seven year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018.
93. Salpeter SR, Sauders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low risk tuberculin reactors older than 35 yrs of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997;127:1051-1061.
94. Joint Tuberculosis Committee, British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-548.
95. Centers for Disease Control and Prevention. Use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons. MMWR 1998;47:911-912.
96. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-647.
97. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR 2003;52:735-739.
98. Telzak EE, Sepkowitz K, Alpert P, et al. Multi-drug resistant tuberculosis in patients without HIV infection. N Engl J Med 1995;333:907-911.
99. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-791.
100. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. JAMA 1993;270:65-68.
101. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-1184.
102. Gilbert DN, Moellering RC, Sande MA. The Sanford Guide to Antimicrobial Therapy, ed. 32. Hyde Park, VT: Antimicrobial Therapy; 2002.
103. Yoshikawa TT, Nagami PH. Adverse drug reactions in TB therapy: risks and recommendations. Geriatrics 1982;37:61-68.
104. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis 1994;18:421.